文献速递胸部肿瘤

Ⅰ期非小细胞肺癌生存改善:VA中央癌症登记分析

Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis.
PubMed 文献 · J Thorac Oncol · 2017-09-23

该研究基于美国退伍军人事务部中央癌症登记数据库,纳入2001至2010年确诊并接受手术或放疗的Ⅰ期非小细胞肺癌患者共11997例。结果显示4年总生存率从38.9%升至53.2%,放疗和手术技术改进与生存改善同步;立体定向体部放疗较常规分割放疗显著改善总生存(HR=0.60)。

要点

  • 2001至2010年Ⅰ期NSCLC患者4年总生存率从38.9%升至53.2%。
  • SBRT较常规分割放疗改善总生存(HR=0.60)和肺癌特异性生存(HR=0.39)。
  • 手术较放疗改善总生存(HR=0.36)和肺癌特异性生存(HR=0.31)。

核心结论

  • 2001至2010年退伍军人Ⅰ期NSCLC患者总生存率提高,与放疗和手术技术改进同步。

研究设计与样本

  • 回顾性队列分析,查询美国退伍军人事务部中央癌症登记数据库,纳入2001至2010年确诊并接受手术或放疗的Ⅰ期NSCLC患者11997例。
  • 采用倾向性评分匹配和Cox多因素分析校正基线患者特征。

主要发现

  • 全部患者4年总生存率从2001年的38.9%升至2010年的53.2%。
  • 放疗患者4年总生存率从12.7%升至28.5%;SBRT较常规分割放疗改善总生存(HR=0.60,95%CI 0.54-0.68)和肺癌特异性生存(HR=0.39,95%CI 0.32-0.46)。
  • 手术患者4年总生存率从51.5%升至66.5%,与辅助化疗使用、电视辅助胸腔镜手术增加及全肺切除率下降相关;开胸与电视辅助胸腔镜手术生存相似。
  • 肺叶切除总生存优于亚肺叶切除(HR=0.82,95%CI 0.75-0.89)。
  • 在SBRT可用时代(2008-2010),医学上不适合患者(Charlson合并症指数=2)亚肺叶切除与肺叶切除的4年总生存无显著差异(55.4% vs 58.1%,p=0.69);适合患者(Charlson合并症指数=0-1)亚肺叶切除的4年总生存显著更差(55.5% vs 68.0%,p<0.001)。

关键数值与推荐

  • 全部患者4年总生存率从2001年38.9%升至2010年53.2%。
  • SBRT较常规分割放疗:总生存HR=0.60(95%CI 0.54-0.68),肺癌特异性生存HR=0.39(95%CI 0.32-0.46)。
  • 手术较放疗:总生存HR=0.36(95%CI 0.35-0.38),肺癌特异性生存HR=0.31(95%CI 0.29-0.33)。
  • 肺叶切除较亚肺叶切除:总生存HR=0.82(95%CI 0.75-0.89)。
  • 医学上不适合患者(Charlson合并症指数=2)亚肺叶切除与肺叶切除4年总生存分别为55.4%和58.1%(p=0.69);适合患者(Charlson合并症指数=0-1)分别为55.5%和68.0%(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The combined impact of advances in diagnosis and treatment of stage I NSCLC has not been assessed comprehensively. To define the survival impact of modern staging and treatment techniques for clinical stage I NSCLC, the Veterans Administration Central Cancer Registry, a database of U.S. veterans in whom the disease was diagnosed in the Veteran's Health Administration, was queried. From this database, patients who had stage I NSCLC diagnosed from 2001 to 2010 and were treated with either surgery or radiation were identified. METHODS: Overall survival (OS) and lung cancer-specific survival were determined. Propensity score matching and Cox multivariate analysis were used to adjust for baseline patient characteristics. RESULTS: A total of 11,997 patients were identified. The 4-year OS rate increased from 38.9% to 53.2% from 2001 to 2010 for all patients. Positron emission tomography and endobronchial ultrasound did not improve OS. Survival of radiated patients improved from 12.7% to 28.5%. The introduction of stereotactic body radiation therapy (SBRT) significantly improved OS (hazard ratio [HR] = 0.60, 95% confidence interval [CI]: 0.54-0.68) and lung cancer-specific survival (HR = 0.39, 95% CI: 0.32-0.46) compared with conventionally fractionated radiation. The 4-year OS rate also improved after surgery (from 51.5% to 66.5%). This increase was associated with use of adjuvant chemotherapy, increased use of video-assisted thoracoscopic surgical procedures, and decreased pneumonectomy rates, with similar survival between open and video-assisted thoracoscopic surgical procedures. OS after lobectomy was superior to that after sublobar resection (HR = 0.82, 95% CI: 0.75-0.89). In the era of available SBRT (2008-2010), 4-year OS was not significantly different after sublobar resection or lobectomy for medically unfit patients (Charlson comorbidity index = 2) (55.4% and 58.1%, respectively; p = 0.69) but was significantly worse for fit patients (Charlson comorbidity index = 0-1) undergoing sublobar resection (55.5% and 68.0%, respectively; p < 0.001). OS (HR = 0.36, 95% CI: 0.35-0.38) and lung cancer-specific survival (HR = 0.31, 95% CI: 0.29-0.33) were improved after surgery as compared with after radiation, with the improvement maintained on matched comparison of lobectomy and SBRT. CONCLUSIONS: OS increased in veterans with a diagnosis of stage I NSCLC from 2001 to 2010; the increase was coincident with improved radiation and surgical techniques.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Boyer MJ, Williams CD, Harpole DH, et al. Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis. J Thorac Oncol. 2017. PMID: 28951090. doi:10.1016/j.jtho.2017.09.1952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。